{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T13:17:35Z","timestamp":1764940655370,"version":"3.46.0"},"reference-count":13,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jtct.2025.11.014","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T13:14:27Z","timestamp":1764940467000},"page":"948-951","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Toward Optimized Real-World Lymphodepletion in Idecabtagene Vicleucel (Ide-cel) Therapy: Lessons from Fludarabine Exposure in Multiple Myeloma"],"prefix":"10.1016","volume":"31","author":[{"given":"Guillaume","family":"Dachy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Poir\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2025.11.014_bib0001","first-page":"989","article-title":"Fludarabine lymphodepletion exposure is associated with toxicities after idecabtagene-vicleucel in relapsed\/refractory multiple myeloma: real-world experience from the US myeloma immunotherapy consortium","volume":"31","author":"Sweiss","year":"2025","journal-title":"Trnsplantation and Cellular Therapy"},{"key":"10.1016\/j.jtct.2025.11.014_bib0002","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1303935","article-title":"Lymphodepletion - an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle","volume":"14","author":"Lickefett","year":"2023","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.jtct.2025.11.014_bib0003","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/s41409-025-02567-5","volume":"60","author":"Orti","year":"2025","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.jtct.2025.11.014_bib0004","doi-asserted-by":"crossref","first-page":"e203","DOI":"10.1016\/S1470-2045(24)00715-0","article-title":"Non-ICANS neurological complications after CAR T-cell therapies: recommendations from the EBMT Practice Harmonisation and Guidelines Committee","volume":"26","author":"Graham","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtct.2025.11.014_bib0005","doi-asserted-by":"crossref","DOI":"10.1038\/s41409-025-02614-1","article-title":"Impact of fludarabine dose on outcome after allo-HSCT with reduced intensity conditioning for older patients with AML","author":"Dachy","year":"2025","journal-title":"Bone Marrow Transplant"},{"issue":"18","key":"10.1016\/j.jtct.2025.11.014_bib0006","doi-asserted-by":"crossref","first-page":"5579","DOI":"10.1182\/bloodadvances.2023010302","article-title":"Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma","volume":"7","author":"Scordo","year":"2023","journal-title":"Blood Adv"},{"issue":"12","key":"10.1016\/j.jtct.2025.11.014_bib0007","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1038\/s41409-024-02413-0","article-title":"A practical guide to therapeutic drug monitoring in busulfan: recommendations from the Pharmacist Committee of the European Society for Blood and Marrow Transplantation (EBMT)","volume":"59","author":"Domingos","year":"2024","journal-title":"Bone Marrow Transplant"},{"issue":"17","key":"10.1016\/j.jtct.2025.11.014_bib0008","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1182\/blood-2018-11-887067","article-title":"The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells","volume":"133","author":"Hirayama","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jtct.2025.11.014_bib0009","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.70062","article-title":"Prognostic significance of immune reconstitution following CD19 CAR T-cell therapy for relapsed\/refractory B-cell lymphoma","volume":"9","author":"Stock","year":"2025","journal-title":"Hemasphere"},{"issue":"9","key":"10.1016\/j.jtct.2025.11.014_bib0010","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.annonc.2022.05.521","article-title":"Bendamustine is safe and effective for lymphodepletion before tisagenlecleucel in patients with refractory or relapsed large B-cell lymphomas","volume":"33","author":"Ghilardi","year":"2022","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.jtct.2025.11.014_bib0011","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1002\/ajh.27069","article-title":"Bendamustine lymphodepletion is a well-tolerated alternative to fludarabine and cyclophosphamide lymphodepletion for axicabtagene ciloleucel therapy for aggressive B-cell lymphoma","volume":"98","author":"Ong","year":"2023","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.jtct.2025.11.014_bib0012","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41408-023-00929-0","article-title":"Bendamustine vs. fludarabine\/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myeloma","volume":"13","author":"Sidana","year":"2023","journal-title":"Blood Cancer J"},{"issue":"7","key":"10.1016\/j.jtct.2025.11.014_bib0013","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jtct.2023.04.007","article-title":"Mechanisms of Resistance and Treatment of Relapse after CAR T-cell Therapy for Large B-cell Lymphoma and Multiple Myeloma","volume":"29","author":"Rejeski","year":"2023","journal-title":"Transplant Cell Ther"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725015647?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725015647?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T13:15:04Z","timestamp":1764940504000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636725015647"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":13,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2666636725015647"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2025.11.014","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Toward Optimized Real-World Lymphodepletion in Idecabtagene Vicleucel (Ide-cel) Therapy: Lessons from Fludarabine Exposure in Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2025.11.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc. on behalf of The American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}